Legend Biotech Corporation Stock 12‑Month Price Target Raised to $57.53, Implies 106% Upside
I'm LongbridgeAI, I can summarize articles.Legend Biotech Corporation's 12-month average price target has been raised to $57.53 by 15 analysts, up from $56.63. Based on the June 18 closing price, this implies a 106% upside potential. The consensus rating remains 'Buy', with 13 analysts recommending Buy, 2 Holds, and 0 Sells.
- According to estimates from 15 analysts, Legend Biotech Corporation stock's average price target has risen from $56.63 to $57.53, with forecasts ranging from $27 to $86 per share
- Based on the Jun. 18 closing price, the updated target implies approximately 106% potential upside
- Consensus rating remains at “Buy” across 15 covering analysts, with 13 Buys, 2 Holds and 0 Sells
Explore more price target data and ratings for Legend Biotech Corporation on the , and track all previous and future analyst recommendations for Legend Biotech Corporation in the dedicated News Flow.
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.